Outcomes that matter.
STAIRWAY prevents more than 80% of respiratory arrests during light and moderate-to-deep sedation — improving patient safety and reducing the cost burden of sedation complications.
With the device, apnoea dropped to a median of zero.
In a randomised controlled trial, participants sedated with the STAIRWAY device had significantly fewer and shorter apnoeic events than the control group — a median of zero, versus three events and 52 seconds of cumulative apnoea without it.
Apnoeic events per participant (median)
P = 0.0015Cumulative apnoea during sedation (median)
P = 0.0039Airway space behind the soft palate Increased with the device — shown by MRI in proof-of-concept studies.
Apnoea data from a randomised controlled trial in 36 sedated healthy volunteers — Ljungvall et al., Eur J Anaesthesiol Intensive Care Med 2026. Airway-space finding from proof-of-concept MRI work.
Read the publication →What changes
in your clinic.
- 01Reduces healthcare costs from complications of sedation
- 02Prevents stress among sedationists
- 03Promotes patient safety and security
$2B per year — preventable.
Complications of procedural sedation are estimated to increase healthcare costs in the US by roughly $2 billion per year. By preventing the most common complications, STAIRWAY can significantly reduce that burden.